Ind-Swift Laboratories' Q3 FY 2025-26 Quarterly Results

Result Summary

• Ind-Swift Laboratories Ltd reported a 4.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 693.7%.
• Its expenses for the quarter were down by 2.5% QoQ and up 562.9% YoY.
• The net profit increased 19.4% QoQ and increased 95300.0% YoY.
• The earnings per share (EPS) of Ind-Swift Laboratories Ltd stood at 1.13 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ind-Swift Laboratories Ltd is a pharmaceutical company known for its focus on the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and formulations. The company operates in the pharmaceutical industry, which has seen significant growth due to ongoing demand for healthcare products. Ind-Swift Laboratories is recognized for its diverse product portfolio, catering to various therapeutic segments. However, specific recent major developments about the company are not available within the provided data.

Revenue

In the third quarter of fiscal year 2026 (Q3FY26), Ind-Swift Laboratories Ltd reported a total income of ₹178.43 crores. This represents a quarter-over-quarter (QoQ) growth of 4.7% compared to ₹170.50 crores in the second quarter of fiscal year 2026 (Q2FY26). On a year-over-year (YoY) basis, there was a substantial increase of 693.7%, as the total income in Q3FY25 was ₹22.48 crores. This significant YoY growth highlights a notable increase in revenue generation compared to the same period in the previous year.

Profitability

The company's profitability metrics for Q3FY26 indicate a profit before tax (PBT) of ₹16.39 crores, which reflects a QoQ increase of 58.5% from ₹10.34 crores in Q2FY26. On a YoY basis, the PBT showed a dramatic change from a loss of ₹1.08 crores in Q3FY25, indicating a positive turnaround. The tax expenses for Q3FY26 amounted to ₹6.87 crores, up by 198.7% QoQ from ₹2.30 crores in Q2FY26 and significantly different from a tax credit of ₹1.08 crores in Q3FY25. Consequently, the profit after tax (PAT) for Q3FY26 was ₹9.54 crores, a 19.4% QoQ increase from ₹7.99 crores in Q2FY26 and a significant YoY improvement from ₹0.01 crores in Q3FY25.

Operating Metrics

The earnings per share (EPS) for Ind-Swift Laboratories Ltd in Q3FY26 stood at ₹1.13, marking a 17.7% increase from ₹0.96 in Q2FY26. This figure was not applicable for YoY comparison as EPS was reported as ₹0.00 in Q3FY25. Total expenses for Q3FY26 were ₹156.19 crores, showing a decrease of 2.5% QoQ from ₹160.16 crores in Q2FY26. On a YoY basis, total expenses grew by 562.9% from ₹23.56 crores in Q3FY25. These metrics provide insights into the company's operational efficiency and cost management over the past year.